CA3239578A1 - Peptides and methods for use in treating pain - Google Patents

Peptides and methods for use in treating pain Download PDF

Info

Publication number
CA3239578A1
CA3239578A1 CA3239578A CA3239578A CA3239578A1 CA 3239578 A1 CA3239578 A1 CA 3239578A1 CA 3239578 A CA3239578 A CA 3239578A CA 3239578 A CA3239578 A CA 3239578A CA 3239578 A1 CA3239578 A1 CA 3239578A1
Authority
CA
Canada
Prior art keywords
peptide
pain
seq
vector
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3239578A
Other languages
English (en)
French (fr)
Inventor
Stephane GAILLARD
Francis CASTETS
Abdelaziz MOQRICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tafalgie Therapeutics
Original Assignee
Tafalgie Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tafalgie Therapeutics filed Critical Tafalgie Therapeutics
Publication of CA3239578A1 publication Critical patent/CA3239578A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3239578A 2021-12-17 2022-12-19 Peptides and methods for use in treating pain Pending CA3239578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306835.6 2021-12-17
EP21306835 2021-12-17
PCT/EP2022/086559 WO2023111348A1 (en) 2021-12-17 2022-12-19 Peptides and methods for use in treating pain

Publications (1)

Publication Number Publication Date
CA3239578A1 true CA3239578A1 (en) 2023-06-22

Family

ID=79317102

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3239578A Pending CA3239578A1 (en) 2021-12-17 2022-12-19 Peptides and methods for use in treating pain

Country Status (12)

Country Link
US (1) US20250051395A1 (cg-RX-API-DMAC7.html)
EP (1) EP4447991A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024547029A (cg-RX-API-DMAC7.html)
KR (1) KR20240126864A (cg-RX-API-DMAC7.html)
CN (1) CN118401249A (cg-RX-API-DMAC7.html)
AR (1) AR129864A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022413983A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239578A1 (cg-RX-API-DMAC7.html)
IL (1) IL313183A (cg-RX-API-DMAC7.html)
MX (1) MX2024007301A (cg-RX-API-DMAC7.html)
TW (1) TW202344689A (cg-RX-API-DMAC7.html)
WO (1) WO2023111348A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Also Published As

Publication number Publication date
TW202344689A (zh) 2023-11-16
JP2024547029A (ja) 2024-12-26
AU2022413983A1 (en) 2024-06-13
KR20240126864A (ko) 2024-08-21
MX2024007301A (es) 2024-06-26
CN118401249A (zh) 2024-07-26
AR129864A1 (es) 2024-10-09
US20250051395A1 (en) 2025-02-13
EP4447991A1 (en) 2024-10-23
WO2023111348A1 (en) 2023-06-22
IL313183A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
US20250051395A1 (en) Peptides and methods for use in treating pain
JP3474190B2 (ja) 合成ポリヌクレオチド
US20250213654A1 (en) Peptides and methods for use in treating pain
AU2019314383A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
AU2019304569B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
JP7380670B2 (ja) Igf-1-暗号化dna作製物及びhgf-暗号化dna作製物を用いた神経病症治療
JP2024527742A (ja) アデノ随伴ウイルス粒子及びその使用方法
RU2597789C2 (ru) Анальгетическое средство на основе плазмидной днк, кодирующей hnp-1, либо hnp-2, либо hnp-3 (варианты)
OA22140A (en) Peptides and methods for use in treating pain.
JP2019070001A (ja) 肝細胞増殖因子及びストローマ細胞由来因子1αを用いた末梢動脈疾患の予防または治療用組成物
KR20200074167A (ko) 가바펜티노이드로부터의 간섭이 감소되고 hgf 이형체들을 발현하는 dna 컨스트럭트를 이용하는 신경병증의 치료
OA22072A (en) Peptides and methods for use in treating pain.
CN107075501B (zh) 炎症报道系统
WO2021010303A1 (ja) 顕性型変異遺伝子に由来する疾患の治療剤
CN116672435A (zh) LRP1-β链短肽在治疗胰岛素抵抗和糖尿病中的应用
CN117003854A (zh) 用于预防或治疗骨关节炎的蛋白组合物、mRNA组合物及用途
CN110904046B (zh) Islr基因在制备治疗肥胖及改善胰岛素抵抗的药物中的应用
KR20130126549A (ko) 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료
US20250194571A1 (en) Compositions and methods for defining optimal treatment timeframes in lysosomal disease
US20250313643A1 (en) Humanized non-opioid composition and therapies for pain management
WO2015134833A2 (en) Therapeutic proteins for treating cancers and methods for using such proteins
CN121693571A (zh) 用于治疗中枢神经系统蛋白质病的重组腺相关病毒载体
Xu The Effect of Neonatal Administration of Recombinant Myostatin Propeptide on Skeletal Muscle Growth in Mice.

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241022

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241127

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251125